Abstract Number: PB1087
Meeting: ISTH 2021 Congress
Background: Edoxaban is a direct oral anticoagulant and does not require monitoring, however it could be useful in certain situations.
Aims: To check the anticoagulant activity of edoxaban, measured with the Low Molecular Weight Heparin (LMWH) calibrated anti-Xa assay.
Methods: Samples were obtained one month after the beginning of the treatment, at the through (median time of 19h). We do not have the edoxaban specific calibrator, as we work with the ACL TOP 500 (Werfen®), so we used the LMWH calibrated anti-Xa assay. We used the cut-off < 0.10UI/mL for excluding the presence of clinically relevant concentration of anti-Xa inhibitor.
Results: 36 patients were studied from 2018 to 2020. 32 were anticoagulated because of atrial fibrillation and 2 for venous thrombosis. 18 were on 60mg and 18 on 30mg. 7 had the 30mg dose, because of low weight, with a median weight of 55kg (40-63) and 10 because of creatinine clearance (CrCl) <50mL/min, with a median CrCl of 41 mL/min (21-41). Only 1 patient fulfilled both criteria.
Median age of patients on 60mg was 78 (57-93), 66,6% were women (12 ) and 33,3% (6) were men. Median age in the group of 30mg, was 81 ( 50-92), 72% were women (13) and 28% (5) were men.
3 patients had an anti-Xa activity <0.10 IU/mL, confirmed in two other different times, all of them were on 60mg. 1 out of 3 had a CrCl>95mL/min and the other 2 a CrCl >88 mL/min. None of them had any drug interaction or a cause that justified it.
Conclusions: We found 3 patients taking edoxaban 60mg with no clinically relevant anticoagulant activity and only one had an obvious cause, a CrCl>95mL/min. Hence, it could be useful to check the anticoagulant activity of edoxaban, in the first months of treatment in order to confirm the patient is correctly anticoagulated.
To cite this abstract in AMA style:García-León N, Calderon-López MT, Matilla-García A. Should We Check the Anticoagulant Activity Of Edoxaban, at Least at the Beginning of the Treatment? [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/should-we-check-the-anticoagulant-activity-of-edoxaban-at-least-at-the-beginning-of-the-treatment/. Accessed November 30, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/should-we-check-the-anticoagulant-activity-of-edoxaban-at-least-at-the-beginning-of-the-treatment/